What it is
HCG stands for Human Chorionic Gonadotropin. It is a glycoprotein hormone — a protein with sugar chains attached, rather than a simple peptide — made by the placenta during pregnancy. In women it keeps the corpus luteum going and supports early pregnancy, thickens the lining of the womb, and raises oestrogen and progesterone. As a fertility treatment it is used as a trigger shot alongside IVF or IUI, causing ovulation within 36 hours. It can raise the chance of a multiple pregnancy and should be stopped once conception has happened.
In men it matters because its structure is almost identical to luteinising hormone (LH), one of the two signals the brain sends to the testicles. When you inject HCG, it goes straight to the Leydig cells in the testicles and tells them to make testosterone. It skips the brain entirely. That is why it is used for hypogonadism, low testosterone, infertility, and to prevent the shrinking testicles and falling sperm count caused by testosterone therapy or anabolic steroid use.
HCG was first isolated in the 1920s and has been used in medicine since the 1930s. It is FDA approved for male hypogonadism and some kinds of infertility. In March 2020 it was reclassified as a biologic product, which stopped compounding pharmacies from making cheaper versions and made it harder for many men on TRT to get.
It is dosed in international units (IU), a measure of biological activity, not in milligrams.
Human chorionic gonadotropin is a placental glycoprotein hormone — an alpha/beta heterodimer with attached carbohydrate chains, structurally distinct from the simple peptides elsewhere on this site — produced by the syncytiotrophoblast. In women it sustains the corpus luteum and early pregnancy, thickens the endometrium, and drives increased oestrogen and progesterone output. Therapeutically it serves as an ovulation trigger in IVF and IUI cycles, inducing ovulation within 36 hours; it raises the risk of multiple pregnancy and is discontinued immediately after conception.
Its beta subunit is near-identical to luteinising hormone, making it a direct LH-receptor agonist at Leydig cells. It bypasses the hypothalamus and pituitary entirely, which is why it maintains intratesticular testosterone and testicular volume during exogenous androgen exposure, and why it works in secondary hypogonadism where the defect is upstream signalling rather than testicular failure.
First isolated in the 1920s and in clinical use since the 1930s, HCG is FDA approved for male hypogonadism and certain infertility indications. In March 2020 the Biologics Price Competition and Innovation Act reclassified it as a biologic, removing it from the 503A/503B compounding exemptions under the Federal Food, Drug, and Cosmetic Act. A 2023 Fertility and Sterility study found that of 13 outsourcing pharmacies compounding gonadotropins nationally, 61.5% halted operations after March 2020, with 75% citing the FDA mandate.
Half-life is approximately 24 to 36 hours versus roughly 30 minutes for endogenous LH. Dosing is in international units of biological activity, not mass.
How it works
Your body makes testosterone through a chain of three signals. The hypothalamus in the brain releases GnRH. That tells the pituitary gland to release two hormones, LH and FSH. LH travels to the Leydig cells in the testicles and tells them to make testosterone. FSH travels to the Sertoli cells and tells them to make sperm.
HCG copies LH. It fits the same docking sites on the Leydig cells and produces the same testosterone response. The big difference is how long it lasts. Natural LH is cleared in about 30 minutes. HCG stays active for about 24 to 36 hours, so it can be injected every other day or three times a week.
When a man injects testosterone, the brain sees plenty of testosterone and switches the whole chain off. GnRH, LH, and FSH all fall, the testicles stop getting their signal, and they shrink. HCG works around this because it does not need the brain at all — it tells the testicles directly to keep going.
There is one important limit. HCG copies LH, not FSH. So it handles testosterone production well, but it does not fully cover sperm production on its own. If fertility is the main goal, it may need to be paired with HMG or recombinant FSH.
HCG also increases the amount of testosterone that converts into oestrogen inside the testicles. This is why oestrogen can rise, especially at higher doses or in men carrying more body fat.
Testosterone production runs through the HPG axis: hypothalamic GnRH drives pituitary release of LH and FSH; LH acts on Leydig cells to produce testosterone, FSH acts on Sertoli cells to support spermatogenesis.
HCG binds the same LH receptor on Leydig cells and triggers the same steroidogenic cascade. The pharmacokinetic distinction is decisive: LH has a half-life of approximately 30 minutes, HCG approximately 24 to 36 hours, giving sustained receptor stimulation and permitting every-other-day or three-times-weekly dosing.
Exogenous testosterone produces negative feedback at the hypothalamus and pituitary, suppressing GnRH, LH, and FSH. Leydig and Sertoli cells lose their stimulus and the testes atrophy. Because HCG acts at the receptor level rather than upstream, it maintains intratesticular testosterone irrespective of axis suppression. Coviello et al. (2005) showed intratesticular testosterone fell 94% on testosterone alone, while 500 IU every other day held it 26% above baseline.
The limitation is that HCG provides LH activity only. FSH-dependent spermatogenesis is supported indirectly via intratesticular testosterone but not driven directly, so fertility protocols may require HMG or recombinant FSH in addition.
HCG also stimulates intratesticular aromatase, converting a portion of the newly produced testosterone to oestradiol. This is the mechanism behind the dose-dependent oestrogen elevation and gynaecomastia risk, and it is amplified in men with higher adiposity.
On desensitisation: Hsieh et al. (1984) found a single 1,500 IU dose peaked testosterone at 2.1 times baseline at 48 hours then fell below normal by day 7, whereas divided small doses did not desensitise and enhanced Leydig cell steroidogenesis. Desensitisation is associated with single doses above 5,000 IU or prolonged high-dose protocols, not with standard 250 to 500 IU dosing.
What it does
In men, HCG acts like LH. It makes the Leydig cells in the testicles produce testosterone and it supports sperm production. During testosterone therapy it keeps the testicles full and working when the body's own signal has been switched off, so they do not shrink, ejaculate volume holds up, and fertility is preserved.
Used on its own in men whose problem is weak signalling from the brain rather than failed testicles, it can raise testosterone. In a 2022 study of 20 men, testosterone rose from 362 to 520 ng/dL, a 49.9% increase, and half reported feeling better. This is usually a smaller and less predictable rise than testosterone therapy gives.
It also relieves the symptoms that come with low testosterone — fatigue, stress, low sex drive, and depression — and raises sperm count.
In women it maintains a pregnancy, supports the developing baby, thickens the lining of the womb, and raises oestrogen and progesterone. As a fertility treatment it triggers ovulation within 36 hours of the injection.
Some people notice temporary heart palpitations or anxiety from the surge in hormone signal. This usually fades with continued use.
Male: LH-receptor agonism at Leydig cells drives intratesticular and systemic testosterone and supports spermatogenesis in the seminiferous tubules, maintaining testicular volume and ejaculate volume. During exogenous androgen exposure it substitutes for suppressed LH, preserving intratesticular testosterone — which peripheral testosterone does not — and thereby preventing atrophy, falling sperm count, and infertility.
As monotherapy in secondary hypogonadism, Zucker et al. (2022) reported total testosterone rising from 362 to 520 ng/dL (49.9%) in 20 men on approximately 2,000 IU weekly, with 50% reporting symptom improvement and no significant change in PSA or haematocrit; some studies showed a slight haematocrit decrease. Response is variable and generally less robust than TRT.
Clinically it addresses the deficiency symptom cluster — fatigue, stress, low libido, depression — and restores fertility parameters. It sits in the intervention hierarchy between upstream agents (enclomiphene, kisspeptin) and full testosterone replacement.
Female: maintains the corpus luteum and pregnancy, supports fetal development, thickens the endometrium, and raises oestrogen and progesterone. As an ovulation trigger in IVF and IUI cycles it induces ovulation within 36 hours.
Transient palpitations or anxiety attributable to the LH-like surge are reported and usually fade with continued use.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Raises testosterone by acting like luteinising hormone on the Leydig cells in the testicles.Human trials
- Raises sperm count and can help with infertility.Human trials
- Restores sex drive where low testosterone had reduced it.Limited human data
- Helps with the fatigue, stress, low sex drive, and depression that come with testosterone deficiency.Limited human data
- Prevents or reduces the shrinking testicles, falling sperm count, and infertility caused by testosterone therapy or anabolic steroid use.Limited human data
- Increases testicular size and fullness, often within days, and users report better ejaculate volume.Anecdotal
- Keeps the testicles working during testosterone therapy without interfering with the therapy itself.Human trials
- Can be used on its own to raise testosterone in secondary hypogonadism, keeping the body's own system active.Human trials
- Users report improved mood and general well-being when it is added to TRT.Anecdotal
- In women: maintains a pregnancy and supports the developing baby.Human trials
- In women: thickens the lining of the womb and increases oestrogen and progesterone.Limited human data
- In women: triggers ovulation within 36 hours, increasing the chance of pregnancy alongside IVF or IUI.Human trials
- Direct Leydig cell stimulation raising intratesticular and systemic testosterone.Human trials
- Supports spermatogenesis; raises sperm count and addresses infertility.Human trials
- Restores libido in hypogonadal men.Limited human data
- Addresses the deficiency symptom cluster: fatigue, stress, low libido, depression.Limited human data
- Mitigates gonadal atrophy, falling sperm count, and infertility from exogenous androgen exposure; Coviello et al. (2005) showed 500 IU every other day held intratesticular testosterone 26% above baseline versus a 94% drop on testosterone alone.Limited human data
- Increases testicular volume, with return of fullness typically within the first week; ejaculate volume improvement widely reported.Anecdotal
- Maintains intratesticular testosterone during TRT, which peripheral testosterone does not.Human trials
- Monotherapy option in secondary hypogonadism: testosterone 362 to 520 ng/dL (49.9%) in Zucker et al. (2022), with 50% symptom improvement.Human trials
- No significant PSA or haematocrit change in cited studies; slight haematocrit decrease in some, a potential secondary benefit for men on TRT.Limited human data
- Users report improved mood and well-being on adding HCG to TRT.Anecdotal
- Female: maintains the corpus luteum and pregnancy; supports fetal development.Human trials
- Female: endometrial thickening; increased oestrogen and progesterone.Limited human data
- Female: ovulation trigger with a 36-hour window alongside IVF or IUI.Human trials
What to expect
HCG works faster than most hormone treatments. Most men notice something within the first 1 to 2 weeks.
In the first week, men who have been on testosterone therapy without HCG often feel their testicles fill out again within days. This is the most immediate and obvious change.
Over weeks 2 to 4, testosterone from the HCG settles into a steady level. Some men notice better mood, sex drive, or general well-being, especially if they had been feeling the effects of shut-down testicles.
Fertility takes much longer. Sperm take 70 to 74 days to develop, so expect 3 to 6 months of steady use before sperm counts improve meaningfully. If FSH support is also needed, full recovery can take 12 to 24 months.
Watch oestrogen. Because HCG increases the conversion of testosterone to oestrogen inside the testicles, some men get water retention, mood swings, or sensitive nipples in the first few weeks. This depends on dose and is more common at higher doses and in men with more body fat. If it happens, the first step is to lower the HCG dose, not add another drug. Get oestradiol checked at 4 to 6 weeks.
Onset is rapid relative to other endocrine interventions, with most men noticing effects within 1 to 2 weeks.
Week 1: men previously on TRT without HCG typically report return of testicular fullness within days — the most immediate and consistent effect.
Weeks 2 to 4: testosterone output from Leydig stimulation stabilises. Improvements in mood, libido, and well-being are commonly reported, particularly where testicular suppression had been symptomatic.
Fertility timelines are governed by the 70 to 74 day spermatogenic cycle. Meaningful sperm count improvement requires approximately 3 to 6 months of consistent use; where FSH support is added, maximal spermatogenesis may take 12 to 24 months. Semen analysis every 3 months tracks progress.
Oestrogen is the main variable to monitor. Intratesticular aromatase stimulation produces dose-dependent oestradiol elevation, presenting as water retention, mood changes, or nipple sensitivity within the first weeks, more pronounced above 500 IU per injection and in men with higher body fat. Users frequently report needing to reduce HCG or testosterone dose rather than add an aromatase inhibitor. Check oestradiol at 4 to 6 weeks, alongside total and free testosterone; LH and FSH are informative only in monotherapy since they are suppressed on TRT; PSA if over 40.
Concern about HCG "stopping working" is common in practice but, at 250 to 500 IU three times weekly, rarely reported; true Leydig desensitisation is tied to single doses above 5,000 IU.
Reconstitution and dosing
Read this first: HCG is dosed in international units (IU), not micrograms. IU measure biological activity, not weight, so there is no microgram equivalent. The dose column shows IU, and the units-to-draw column is worked out from the vial strength and how much bacteriostatic water you add.
The standard vial is 5,000 IU mixed with 2 mL of bacteriostatic water, giving 250 IU per 10 units on an insulin syringe. A 1,000 IU vial is mixed with 1 mL. Add the water slowly down the inside of the vial and swirl gently. Keep it in the fridge after mixing and use within 30 to 60 days.
Inject under the skin. HCG lasts about 24 to 36 hours, so daily dosing is unnecessary; pick fixed days such as Monday, Wednesday, Friday.
With TRT (maintenance): 250 to 500 IU per injection, three times a week (750 to 1,500 IU a week), for as long as you are on TRT.
On its own (monotherapy): 500 to 1,000 IU per injection, three times a week (1,500 to 3,000 IU a week), ongoing with regular blood tests.
Fertility recovery: start at 500 IU every other day for at least 3 to 6 months. Check a semen analysis every 3 months. If sperm count does not recover, add HMG or rFSH at 75 IU every other day. Full recovery may take 12 to 24 months.
Other patterns users follow: a low dose of 250 to 500 IU three times a week; a 500 IU three-days-a-week protocol for 12 weeks; a high-dose restart of 1,500 IU three times a week for four weeks, then 2,000 IU, then down to 1,000 IU, with the 5,000 IU protocols run 8 to 16 weeks and rested 8 to 16 weeks; TRT support at 500 to 1,500 IU one to three times a week; post-cycle 1,000 to 3,000 IU one to three times a week; and 1,500 to 5,000 IU two to three times a week for fertility restoration. For women, the ovulation trigger is a single 5,000 IU injection — 200 units of liquid, so two 100-unit syringes or four 50-unit syringes.
Avoid very large single doses: more than 5,000 IU at once can make the testicles stop responding.
Unit convention. Doses are international units of biological activity; the dose column reports IU directly, and draw figures are computed from vial strength over diluent volume.
Standard reconstitution: 5,000 IU in 2 mL bacteriostatic water, 250 IU per 10 insulin units (25 IU per unit). A 1,000 IU vial in 1 mL gives 10 IU per unit. Refrigerate after reconstitution; use within 30 to 60 days.
Subcutaneous administration. No published dose-finding studies compare subcutaneous with intramuscular routes for TRT-clinic protocols. Half-life 24 to 36 hours supports every-other-day or three-times-weekly dosing.
Evidence base. Coviello et al. (2005): 250 to 500 IU every other day maintains intratesticular testosterone at or above baseline under exogenous testosterone; 500 IU produced 26% above baseline. Lee and Ramasamy (2018): approximately 1,500 IU weekly across 3 injections. Zucker et al. (2022) monotherapy: approximately 2,000 IU weekly.
With TRT (maintenance): 250 to 500 IU per injection, 3×/week (750 to 1,500 IU/week), subcutaneous, ongoing while on TRT.
Monotherapy: 500 to 1,000 IU per injection, 3×/week (1,500 to 3,000 IU/week), ongoing with regular bloodwork.
Fertility recovery: 500 IU every other day for 3 to 6 months minimum; semen analysis every 3 months; if sperm count does not recover, add HMG or rFSH at 75 IU every other day. Full recovery may take 12 to 24 months.
Additional patterns seen in practice: low-dose physiological mimicry at 250 to 500 IU 3×/week; 500 IU 3 days/week for 12 weeks; HPTA restart after prolonged AAS use or severe hypogonadotropic hypogonadism at 1,000 to 2,500 IU per injection 3×/week — weeks 1-4 at 1,500 IU, weeks 4-8 at 2,000 IU, weeks 9-12 at 1,000 IU — with 5,000 IU protocols run 8-16 weeks and an 8-16 week washout; TRT support 500-1,500 IU 1-3×/week; post-cycle 1,000-3,000 IU 1-3×/week; fertility restoration 1,500-5,000 IU 2-3×/week. Female ovulation trigger: single 5,000 IU (200 units of solution).
Oestrogen management: reduce HCG dose first rather than adding an aromatase inhibitor. Avoid single doses above 5,000 IU given Hsieh et al. (1984) desensitisation data.
Standard (with TRT), 5000 IU vial
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 250 IU | 10 units | 3×/week |
| Full | 500 IU | 20 units | 3×/week |
Standard (monotherapy), 5000 IU vial
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 500 IU | 20 units | 3×/week |
| Full | 1,000 IU | 40 units | 3×/week |
Standard (fertility recovery), 5000 IU vial
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 500 IU | 20 units | every other day |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 1,000 IU vial — low dose protocol (mimics natural luteinising hormone levels)
Mix with 1 mL (100 units) of bacteriostatic water.
10 IU per unit
Cycle: Depends on application · Frequency: 3×/week, morning preferred; subcutaneous or intramuscular; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| 250 IU | 250 IU | 25 units | 3×/week |
| 375 IU | 375 IU | 37.5 units | 3×/week |
| 500 IU | 500 IU | 50 units | 3×/week |
Alternative, 5,000 IU vial — standard protocol, 1,500 IU/week (maintains testosterone inside the testicles during testosterone therapy and preserves fertility)
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
Cycle: 12 weeks; the 5,000 IU protocols run 8–16 weeks then an 8–16 week washout · Frequency: 3 days per week, same days and times where possible; morning preferred
| When | Dose | Draw | How often |
|---|---|---|---|
| 500 IU | 500 IU | 20 units | 1×/day on 3 days per week, for 12 weeks |
Alternative, 5,000 IU vial — high dose protocol (restarting testosterone production after prolonged anabolic steroid use or severe hypogonadotropic hypogonadism)
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
Cycle: 12 weeks; the 5,000 IU protocols run 8–16 weeks then an 8–16 week washout · Frequency: 3×/week subcutaneously; 1,000–2,500 IU per injection
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 — 1,500 IU | 1,500 IU | 60 units | 3×/week |
| Weeks 4–8 — 2,000 IU | 2,000 IU | 80 units | 3×/week |
| Weeks 9–12 — 1,000 IU | 1,000 IU | 40 units | 3×/week |
Alternative, 5,000 IU vial — low dose protocol (mimics natural luteinising hormone levels)
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
Cycle: Depends on application · Frequency: 3×/week; morning preferred
| When | Dose | Draw | How often |
|---|---|---|---|
| 250 IU | 250 IU | 10 units | 3×/week |
| 375 IU | 375 IU | 15 units | 3×/week |
| 500 IU | 500 IU | 20 units | 3×/week |
Alternative, 5,000 IU vial — ovulation trigger (women), one-time injection
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
Frequency: Single injection; 200 units of solution — load two 100-unit syringes or four 50-unit syringes
| When | Dose | Draw | How often |
|---|---|---|---|
| 5,000 IU | 5,000 IU | 200 units(over 100 units: split across 2 syringes) | one-time |
Alternative, General ranges given without a vial size (5,000 IU vial assumed for the draw figures)
Mix with 2 mL (200 units) of bacteriostatic water.
25 IU per unit
Frequency: See each row
| When | Dose | Draw | How often |
|---|---|---|---|
| Standard TRT support — 500 IU, low end of 500–1,500 IU | 500 IU | 20 units | 1–3×/week |
| Standard TRT support — 1,500 IU, top of range | 1,500 IU | 60 units | 1–3×/week |
| Bodybuilding post-cycle — 1,000 IU, low end of 1,000–3,000 IU | 1,000 IU | 40 units | 1–3×/week |
| Bodybuilding post-cycle — 3,000 IU, top of range | 3,000 IU | 120 units(over 100 units: split across 2 syringes) | 1–3×/week |
| High dose fertility / restoration — 1,500 IU, low end of 1,500–5,000 IU | 1,500 IU | 60 units | 2–3×/week |
| High dose fertility / restoration — 5,000 IU, top of range | 5,000 IU | 200 units(over 100 units: split across 2 syringes) | 2–3×/week |
The calculator works in milligrams; this compound is dosed in IU, use the table.
Who should avoid it
- Anyone who has ever had an allergic reaction to HCG.
- Anyone with precocious puberty — puberty starting unusually early.
- Anyone with a hormone-related cancer, such as prostate or breast cancer.
- Anyone with a cancer or tumour of the breast, ovary, or uterus.
- Anyone with certain types of ovarian cyst.
- Anyone with uncontrolled thyroid or adrenal problems.
- Anyone with a cancer or tumour of the hypothalamus or pituitary gland — the two brain structures that control hormones.
- Anyone with vaginal bleeding of unknown cause.
- Anyone who is pregnant.
- Men with primary hypogonadism, where the testicles themselves cannot respond. HCG sends a signal; it cannot fix testicles that are unable to answer it.
- Talk to a doctor before using HCG if you have a thyroid or adrenal disorder, an ovarian cyst, unexplained vaginal bleeding, heart disease, liver disease, kidney disease, epilepsy, migraines, or asthma.
- Use with caution if you are prone to high oestrogen or have had gynaecomastia in the past — get oestradiol checked.
- Use with caution if you have polycythaemia or a high haematocrit (thick blood from too many red cells).
- Bloodwork matters: oestradiol at 4 to 6 weeks after starting, total and free testosterone, LH and FSH if using HCG on its own, a semen analysis if fertility is the goal, and PSA if over 40.
- Prior allergic reaction to HCG.
- Precocious puberty.
- Hormone-dependent malignancy, e.g. prostate or breast cancer.
- Carcinoma or tumour of the breast, ovary, or uterus.
- Certain ovarian cyst types.
- Uncontrolled thyroid or adrenal dysfunction.
- Hypothalamic or pituitary tumour.
- Vaginal bleeding of unknown cause.
- Pregnancy.
- Primary hypogonadism: Leydig cells that cannot respond to LH-receptor stimulation will not respond to HCG either — the defect is in the machinery, not the signal.
- Physician consultation required before use in: thyroid or adrenal disorder, ovarian cyst, unexplained vaginal bleeding, cardiac disease, hepatic disease, renal disease, epilepsy, migraine, asthma.
- Caution in men prone to elevated oestradiol or with a history of gynaecomastia; monitor oestradiol.
- Caution in polycythaemia or elevated haematocrit.
- Monitoring: oestradiol at 4 to 6 weeks after initiation; total and free testosterone; LH and FSH (suppressed on TRT, informative under monotherapy); semen analysis where fertility is the goal; PSA if over 40.
Side effects
- Headache.
- Fatigue.
- Restlessness and/or irritability, and mood changes.
- Pain or irritation at the injection site.
- Tenderness or swelling in the breasts, and nipple sensitivity.
- Swelling and water retention.
- Increased body fat, linked to higher oestrogen.
- Depression.
- Gynaecomastia — growth of breast tissue in men. HCG raises oestrogen because some of the extra testosterone made in the testicles converts to oestrogen. This depends on dose and is more common at higher doses and in men with more body fat. If symptoms appear, the first step is to lower the HCG dose rather than add an oestrogen blocker.
- Some people get temporary heart palpitations or anxiety from the surge in luteinising hormone. This usually fades with continued use.
- Rare but serious: blood clots, linked to high-dose protocols. Warning signs are pain, warmth, redness, extreme dizziness, severe headache, numbness or tingling in the hands and feet, and confusion.
- Rare but serious: Ovarian Hyperstimulation Syndrome. Warning signs are severe pelvic pain, nausea and vomiting, diarrhoea, difficulty breathing, a swollen stomach, swollen legs or hands, rapid weight gain, and passing less urine.
- Rare but serious: early puberty in young boys.
- Rare: allergic reaction.
- Very high single doses (above 5,000 IU at once) can make the testicles temporarily stop responding. Standard doses split into smaller injections do not cause this.
- Good news from the studies: no meaningful change in PSA or haematocrit, and some studies showed a slight drop in haematocrit.
What the evidence shows
HCG has been used in medicine since the 1930s and is well studied.
The key trial is Coviello et al. (2005). Twenty-nine healthy men took 200 mg testosterone enanthate a week plus either placebo or 125, 250, or 500 IU HCG every other day for 3 weeks. With placebo, testosterone inside the testicles fell by 94%. With 125 IU it was 25% below baseline, with 250 IU it was 7% below, and with 500 IU it was 26% above baseline. This is why low-dose HCG is the standard add-on to testosterone therapy.
Lee and Ramasamy (2018) reviewed HCG for fertility in men with low testosterone. They recommended 500 IU every other day, optional clomiphene for men wanting a pregnancy, and adding FSH at 75 IU every other day if sperm production has not recovered after 4 to 6 months.
Zucker et al. (2022) gave 20 men with low-testosterone symptoms about 2,000 IU a week of HCG on its own. Testosterone rose from 362 to 520 ng/dL, a 49.9% increase, and 50% reported feeling better. PSA and haematocrit did not change meaningfully.
On the worry that HCG stops working: a Journal of Clinical Endocrinology and Metabolism study found a single 1,500 IU dose pushed testosterone to 2.1 times baseline at 48 hours, then below normal by day 7. Splitting the dose into small, frequent injections did not cause this and actually improved testicle function.
A 2023 Fertility and Sterility paper found that after the FDA reclassified HCG as a biologic in March 2020, 61.5% of 13 compounding pharmacies stopped making it, with 75% blaming the FDA rule. This made HCG harder and more expensive to get.
HCG has decades of clinical use and a solid mechanistic and trial base.
Coviello et al. (2005), Journal of Clinical Endocrinology and Metabolism: 29 men with normal reproductive physiology received 200 mg testosterone enanthate weekly with saline placebo or 125, 250, or 500 IU HCG every other day for 3 weeks. Intratesticular testosterone fell 94% on placebo, sat 25% below baseline at 125 IU, 7% below at 250 IU, and 26% above baseline at 500 IU. This is the foundation for low-dose HCG in TRT protocols.
Lee and Ramasamy (2018), Translational Andrology and Urology: review recommending 500 IU every other day for intratesticular testosterone maintenance, optional clomiphene for men desiring pregnancy, and FSH at 75 IU every other day if HCG alone fails to restore spermatogenesis after 4 to 6 months — reflecting HCG's LH-only activity with no FSH agonism.
Zucker et al. (2022), International Brazilian Journal of Urology: 20 men with hypogonadal symptoms and mean total testosterone above 300 ng/dL received approximately 2,000 IU weekly as monotherapy. Total testosterone rose from 362 to 520 ng/dL (49.9%); 50% reported symptomatic improvement. No significant change in PSA or haematocrit; some studies showed a slight haematocrit decrease.
Leydig cell desensitisation: a Journal of Clinical Endocrinology and Metabolism study found a single 1,500 IU dose produced a testosterone peak of 2.1 times baseline at 48 hours followed by a decline below normal by day 7, whereas divided small-dose administration produced no desensitisation and enhanced Leydig cell steroidogenesis. Desensitisation is associated with single doses above 5,000 IU or prolonged high-dose protocols, not with 250 to 500 IU three times weekly.
Regulatory: a 2023 Fertility and Sterility paper documented that after the March 2020 BPCI Act reclassification of HCG as a biologic, 61.5% of 13 outsourcing pharmacies compounding gonadotropins halted operations, 75% citing the FDA mandate. No published dose-finding studies compare subcutaneous with intramuscular administration for TRT-clinic protocols.
User reports
From public forums
Users report that the most obvious change is the testicles filling out again. Men who were on testosterone therapy without HCG often notice this within the first week. Larger ejaculate volume is also widely reported.
Many users report better mood and a general sense of well-being once HCG is added to their testosterone protocol. The reason for this is not well studied.
The most common complaint is high oestrogen: water retention, mood swings, and sensitive nipples, especially at doses above 500 IU per injection. Many report having to adjust their protocol or lower their testosterone dose to fix this.
Some users worry that HCG stops working over time. In practice this mostly seems to be a dosing issue rather than the testicles genuinely switching off. Men on standard doses of 250 to 500 IU three times a week rarely report it.
Aggregated anecdotal reports carry less weight than the published data but are consistent.
Rapid return of testicular fullness is the most frequently reported effect, typically within the first week in men previously on TRT without HCG; increased ejaculate volume is also common.
Improved mood and well-being are widely reported after adding HCG to a TRT protocol. Some users attribute this to maintained intratesticular testosterone and the neurosteroid pathways it supports, though the mechanism is not well studied.
Oestradiol elevation is the dominant negative report: water retention, mood swings, and nipple sensitivity, particularly above 500 IU per injection. Users frequently reduce their testosterone dose or otherwise adjust the protocol to compensate.
Concern about HCG 'stopping working' persists in practice, but most cases appear dose-related rather than true Leydig cell receptor desensitisation. Men on 250 to 500 IU three times weekly rarely report it.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
- Testosterone Replacement Therapy (TRT)
The main pairing. Testosterone therapy switches off the body's own signal to the testicles, so they shrink and sperm production falls. HCG replaces that signal, maintaining testicular size and fertility. Watch oestrogen, and lower the HCG dose first if symptoms appear.
The primary indication. Exogenous testosterone suppresses gonadotropin release, collapsing intratesticular testosterone by 94% (Coviello et al., 2005) even while serum levels are normal. HCG restores the LH signal directly, maintaining testicular volume and spermatogenesis. The two act at different points: TRT supplies testosterone, HCG keeps the testes active despite HPG suppression.
- Clomid (Clomiphene Citrate)
Boosts the body's own testosterone signal, which makes it useful after a cycle. Lee and Ramasamy (2018) list it as an optional add-on for men wanting a pregnancy.
SERM acting at the hypothalamic level to increase endogenous gonadotropin output; complements HCG's direct Leydig stimulation in a post-cycle restart. Listed as optional by Lee and Ramasamy (2018) for men desiring pregnancy.
- Aromatase inhibitors (e.g. Arimidex)
Helps control oestrogen while on HCG, since raising testosterone also raises the amount that can convert to oestrogen. The first step when oestrogen symptoms appear is to lower the HCG dose, not to add a blocker.
Manages the oestradiol rise driven by intratesticular aromatase stimulation — the mechanism behind gynaecomastia listed under side effects. The first-line response to oestrogen symptoms is HCG dose reduction rather than adding an inhibitor.
- HMG
HCG only copies luteinising hormone, which drives testosterone. It does not copy FSH, which drives sperm. If sperm count has not recovered after 4 to 6 months on HCG, HMG or rFSH at 75 IU every other day adds the missing piece.
HCG has LH activity but no FSH activity. Where HCG alone has not restored spermatogenesis after 4 to 6 months, HMG (or rFSH) at 75 IU every other day supplies FSH activity at the Sertoli cells, covering both sides of the gonadotropin equation.
Supports injury healing and recovery during hormone therapy.
Supports injury healing and recovery through the hormone therapy period.
Another option for healing and recovery during hormone therapy.
Grouped with BPC-157 for injury healing and recovery during hormone therapy.
Boosts libido and sexual function alongside HCG's hormonal effect.
Melanocortin-driven central arousal, complementing HCG's endocrine correction — different mechanism, same target symptom.
Also supports libido and hormone balance. It works at the very top of the hormone chain in the brain, while HCG works at the bottom on the testicles, so in theory they complement each other. No human studies have tested the combination.
Acts upstream on GnRH neurons at the top of the HPG axis while HCG acts directly on Leydig cells at the bottom. Theoretically complementary — kisspeptin restores the axis rather than bypassing it — but no published human research exists on the combination. Also presented as a natural alternative to HCG for fertility and hormonal balance during testosterone therapy, and in a Kisspeptin + PT-141 + HCG libido and fertility stack.
- Enclomiphene (not recommended with TRT)
Do not pair enclomiphene with testosterone therapy in place of HCG. On testosterone the body's signal is already off; if enclomiphene squeezes out some signal you get testosterone from two sources, more oestrogen, and a brain that cannot regulate it properly. HCG is the right tool for keeping the testicles working on TRT.
Pharmacologically incoherent during TRT. Enclomiphene blocks oestrogen receptors at the hypothalamus and pituitary to raise LH output, but the axis is already suppressed by exogenous testosterone; any LH it does elicit adds a second testosterone source, increasing aromatase substrate and driving oestradiol higher while receptor blockade impairs central regulation. HCG has published data maintaining intratesticular testosterone at baseline; enclomiphene with TRT does not.
Common questions
When should HCG actually be used?
Three situations. You are on testosterone therapy and want to stop your testicles shrinking. You have secondary hypogonadism (a weak signal from the brain) and upstream options like enclomiphene or kisspeptin have not worked. Or you are on testosterone therapy and want to keep your fertility. Outside these, you likely do not need it.
Three indications: testicular atrophy prevention on TRT; secondary hypogonadism unresponsive to upstream agents such as enclomiphene or kisspeptin; fertility preservation on TRT. Outside these scenarios it is generally unnecessary.
Why not use enclomiphene with TRT instead of HCG?
Because it does not make sense. Injected testosterone has already switched off your natural production. If enclomiphene forces out some signal anyway, testosterone now comes from two sources, more of it turns into oestrogen, and your brain cannot regulate that oestrogen because enclomiphene is blocking the receptors. HCG has trial data showing it keeps testosterone inside the testicles at baseline. Enclomiphene with TRT does not.
Exogenous testosterone suppresses endogenous production; any LH release enclomiphene achieves by blocking oestrogen feedback adds a second testosterone source, raising aromatase substrate while central oestrogen receptor blockade removes normal regulation of the resulting oestradiol. HCG has published data (Coviello et al., 2005) maintaining intratesticular testosterone at baseline; enclomiphene with TRT does not.
Will HCG stop working over time?
Not at normal doses. Research shows that small, frequent doses actually improve testicle function rather than wearing it out. The problem only appears with very large single doses above 5,000 IU, not with the 250 to 500 IU used alongside testosterone therapy.
Leydig cell desensitisation is not a clinical concern at therapeutic doses. Divided small-dose administration enhances rather than suppresses Leydig cell steroidogenesis; desensitisation is associated with single doses above 5,000 IU or prolonged high-dose protocols, not 250 to 500 IU three times weekly.
Does HCG raise oestrogen?
Yes. Some of the extra testosterone made inside the testicles converts to oestrogen. The higher the dose, the more this happens, and carrying extra body fat makes it worse. If oestrogen symptoms appear, lower the HCG dose first rather than adding an oestrogen blocker.
Yes. HCG stimulates intratesticular aromatase, converting a fraction of the newly produced testosterone to oestradiol in a dose-dependent manner; excess adiposity increases aromatase activity further. First-line management of oestrogenic symptoms is HCG dose reduction, not adding an aromatase inhibitor. Check oestradiol at 4 to 6 weeks.
Can HCG be used instead of TRT?
Yes, for men whose problem is a weak signal from the brain rather than failed testicles. It can raise testosterone by roughly 40 to 50% in some men, and it keeps your own system running. But results vary, and it usually does not lift testosterone as high or as steadily as direct testosterone therapy.
Yes, in secondary hypogonadism. Monotherapy raises testosterone by roughly 40 to 50% in responders — Zucker et al. (2022) reported 362 to 520 ng/dL at approximately 2,000 IU weekly — while preserving endogenous axis activity. Response is variable and levels are typically lower and less stable than with direct TRT. It will not work in primary hypogonadism.
How long does fertility recovery take?
Sperm take 70 to 74 days to develop, so allow at least 3 to 6 months of steady HCG before expecting sperm counts to improve, with a semen test every 3 months. If counts do not recover, HMG or rFSH at 75 IU every other day is added. Full recovery may take 12 to 24 months.
Spermatogenesis runs a 70 to 74 day cycle, so 3 to 6 months minimum of consistent HCG (500 IU every other day) precedes meaningful sperm count improvement, monitored by semen analysis every 3 months. If counts fail to recover, HMG or rFSH at 75 IU every other day is added; maximal recovery may take 12 to 24 months.
How is HCG reconstituted and stored?
A 5,000 IU vial is mixed with 2 mL of bacteriostatic water, giving 250 IU per 10 units on an insulin syringe. Keep it in the fridge after mixing and use it within 30 to 60 days.
Standard reconstitution: 5,000 IU lyophilised vial with 2 mL bacteriostatic water, yielding 250 IU per 10 units on an insulin syringe. Refrigerate after reconstitution; use within 30 to 60 days.
References
- Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2595-2602.
- Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Translational Andrology and Urology. 2018;7(Suppl 3):S348-S352.
- Zucker I, Manschreck R, Boorjian SA, et al. Human chorionic gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone greater than 300 ng/dL. International Brazilian Journal of Urology. 2022;48(5):884-890.
- Hsieh TC, et al. Differential effect of single high dose and divided small dose administration of human chorionic gonadotropin on Leydig cell steroidogenic desensitization. Journal of Clinical Endocrinology and Metabolism. 1984;58(2):327-331.
- Kim HH, Schlegel PN. Endocrine manipulation in male infertility. Urologic Clinics of North America. 2008;35(2):303-318.
- Shah P, Bhatt A, et al. The availability of gonadotropin therapy from FDA-approved pharmacies for men with hypogonadism and infertility. Fertility and Sterility. 2023;119(5):810-815.
- Madhusoodanan V, Shah P, Joshi A. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. World Journal of Men's Health. 2022;40(3):470-477.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.